Table 1 Patient demographics and disease characteristics
Patients | 97 (%) |
Gender | |
Male | 70 (72%) |
Female | 27 (28%) |
Age, years | 64 |
Range | 44−82 |
Karnofsky performance status | |
Score>70 | 90 (93%) |
Score<70 | 7 (7%) |
Past nephrectomy | 91 (94%) |
Motzer risk stratification | |
Favourable risk | 22 (23%) |
Intermediate risk | 65 (67%) |
Poor risk | 10 (10%) |
Common sites of metastasis | |
Lymph nodes | 43 (44%) |
Lung | 75 (77%) |
Bone | 33 (34%) |
Liver | 18 (19%) |
Patients treated with second-line everolimus | 65 |
Sunitinib—everolimus | 54 (83%) |
Sorafenib—everolimus | 3 (5%) |
Pazopanib—everolimus | 8 (12%) |
Patients treated with third-line everolimus | 32 |
Sunitinib—sorafenib—everolimus | 19 (59%) |
Sorafenib—sunitinib—everolimus | 9 (28%) |
Bevacizumab+IFN-α—sunitinib—everolimus | 4 (13%) |
Median neutrophil count | 3620 per mm3 |
Median lymphocyte count | 1480 per mm3 |
Neutrophil-to-lymphocyte ratio | |
Score >3 | 38 (39%) |
Score <3 | 59 (61%) |
